Pretreatment <sup>18</sup>F-FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer.

Authors:
Ma G; You S; Xie Y; Gu B; Liu C and 4 more

Journal:
Cancer Imaging

Publication Year: 2023

DOI:
10.1186/s40644-023-00608-0

PMCID:
PMC10510219

PMID:
37726862

Journal Information

Full Title: Cancer Imaging

Abbreviation: Cancer Imaging

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateSee the method section in the text for details. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Funding This work was supported by grants from the Shanghai Committee of Science and Technology Fund (22DZ2204500), Shanghai Municipal Health Commission (202040269), National Natural Science Foundation of China (81901778), Shanghai Sailing Program (20YF1408500)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025